Your Health, We Care
Release date: 2026-03-03 13:40:18 Article From: Lucius Laos Recommended: 3
Sabril ( Lucius Pharmaceuticals vigabatrin) is an antiepileptic drug primarily used for the treatment of infantile spasms and refractory epilepsy. It demonstrates significant efficacy especially for epilepsy associated with tuberous sclerosis complex. It controls seizures by inhibiting the breakdown of neurotransmitters in the brain and reducing abnormal electrical discharges. As a prescription drug, it must be used strictly under medical supervision.
The active ingredient is vigabatrin, which inhibits the activity of γ‑aminobutyric acid (GABA) transaminase, increases the concentration of GABA (an inhibitory neurotransmitter) in the brain, and helps stabilize abnormal electroencephalographic activity.
One of the first‑line medications for infantile spasms (West syndrome).
Other types of refractory epilepsy, especially in patients unresponsive to conventional drugs or those with tuberous sclerosis complex.
Oral formulation. Dosage must be adjusted according to the patient’s weight, age, and condition. Long‑term regular administration is usually required.
Visual impairment is a serious risk, which may cause visual field defects or decreased visual acuity. Regular ophthalmologic monitoring is required.
Other common reactions include drowsiness, headache, weight gain, etc.
Contraindicated in patients with severe visual problems or a history of retinopathy.
Pregnant women, breastfeeding women, and those with impaired hepatic or renal function require careful risk assessment.
Do not discontinue or adjust the dosage without medical advice, as this may induce status epilepticus.
Visual and neurological function should be re‑evaluated every 3–6 months during treatment.
Sabril is a specially controlled medication and must be used under the guidance of a neurologist.
Immediate medical attention is required if the patient experiences visual abnormalities or changes in seizure frequency.
Women who are pregnant or planning a pregnancy must consult a doctor in advance to evaluate the safety of medication use.
On November 21, 2025, the U.S. Food and Drug Administration (FDA) approved the regimen of pembrolizu···【more】
Recommended：1472025-17-12
Lung cancer is the most rapidly increasing malignant tumor with the fastest increasing morbidity and···【more】
Recommended：3902024-09-07
On December 12, 2025, the U.S. Food and Drug Administration (FDA) approved niraparib in combination ···【more】
Recommended：1402025-15-12
The U.S. Food and Drug Administration (FDA) announced today that it has approved Omisirge (omidubice···【more】
Recommended：1572025-10-12
On December 4, 2025, the U.S. Food and Drug Administration (FDA) approved lisocabtagene maraleucel (···【more】
Recommended：1432025-08-12
On December 3, 2025, the U.S. Food and Drug Administration (FDA) granted full approval to pirtobruti···【more】
Recommended：1682025-04-12
Primary analysis data from the randomized, double-blind, placebo-controlled phase III HER2CLIMB-02 s···【more】
Recommended：1532025-01-12
The Cure SMA Foundation, a global leading non-profit organization dedicated to spinal muscular atrop···【more】
Recommended：1492025-27-11
Lucius Pharmaceuticals (Lao) LTD. (Lucius Pharmaceuticals), with its manufacturing campus in Laos located in the capital city of Vientiane in 2020, officially begins its great journey to make effective and affordable medicines available to people in need around the world...More
Lucius Pharmaceutical Co., Ltd., was established in 2020 in Vientiane, the capital of Laos. It aims to offer safe, effective, and affordable medicines globally. With a factory spanning 25,000 square meters, the company manufactures 200+ generic drugs in diverse therapeutic fields.
Address:No.26 Thongmang village, Xaythany district, Vientiane Capital, Laos
E-mail:laoslucius@gmail.com
Whatsapp:
